Seegene launches Global Million Clinical Study
July 10, 2026—Seegene has launched the Global Million Clinical Study, which aims to evaluate the clinical utility and potential impact of syndromic PCR testing using real-world data.
Webinars and Sponsored Roundtables — Register Now
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
FDA clears Visby’s at-home multiviral PCR test
July 9, 2026—The FDA has cleared the Visby Medical Flu and COVID-19 at-home PCR test.
Bio-Rad launches Vericheck ddPCR kits for QX700 platform
July 7, 2026—Bio-Rad Laboratories launched its QX700 system-compatible Vericheck ddPCR kit portfolio for quality control workflows in advanced cell and gene therapy development and other biopharma applications.
Epredia launches SlideMate thermal slide printer
July 6, 2026—Epredia has launched sales of the SlideMate thermal slide printer, engineered to help clinical laboratories protect tissue samples, strengthen sample traceability, and streamline workflow efficiency during cancer diagnosis.
Versant expands collaboration with Leica Biosystems
June 30, 2026—Leica Biosystems and Versant Diagnostics are expanding their collaboration to advance digital pathology adoption.
Roche launches Axelios 1 NGS platform
June 29, 2026—Roche has launched the Axelios 1, a next‑generation single-molecule sequencing platform powered by proprietary sequencing by expansion technology.
Thermo Fisher launches LabLink 360 QA software
June 26, 2026—Thermo Fisher Scientific has launched the Thermo Scientific LabLink 360 Quality Assurance software, designed to help clinical laboratories simplify quality control workflows, accelerate QC review and decision-making, improve visibility into QC performance, and manage QC operations.
Merck to acquire Bio-Techne for $11.3 billion
June 25, 2026—Merck (Darmstadt, Germany) has entered into a definitive agreement to acquire Minneapolis-based Bio-Techne Corp. for approximately $11.3 billion.
FDA-approved, at-home ColoSense test now available
June 24, 2026—Labcorp announced that ColoSense, an FDA-approved, at-home test for colorectal cancer screening, is now available for adults ages 45 to 85 who are at average risk for developing CRC.
Liaison Nes group A strep assay gets FDA clearance, CLIA waiver
June 23, 2026—Diasorin has received 510(k) clearance and CLIA waiver from the U.S. Food and Drug Administration for its group A streptococcus assay, for use on the Liaison Nes point-of-care molecular diagnostics platform.